| Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. | |
| | |
MedLine Citation:
|
PMID: 12000204 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Despite treatment advances, major depressive disorder (MDD) is still a significant cause of morbidity and mortality. Current therapies frequently fall short of providing full remission. In addition, physical symptoms are commonly seen in MDD patients, increasing overall morbidity and health care utilization. Duloxetine hydrochloride, a dual reuptake inhibitor of serotonin and norepinephrine, was evaluated for efficacy and tolerability/safety in the treatment of MDD and associated physical symptoms. METHOD: In this multicenter, double-blind, parallel-group study, adult patients with DSM-IV MDD were randomly assigned to receive placebo (N = 122) or duloxetine (60 mg/day, N = 123) for 9 weeks. The primary efficacy measure was the 17-item Hamilton Rating Scale for Depression (HAM-D-17) total score. Painful physical symptoms were assessed using visual analog scales, and global illness and quality of life were evaluated using the Clinical Global Impressions-Severity scale, the Patient Global Impressions-Improvement scale, and the Quality of Life in Depression Scale. Safety and tolerability were determined by monitoring discontinuation rates, adverse events, vital signs, and laboratory results. RESULTS: Duloxetine was significantly superior to placebo (p < .001) in reducing HAM-D-17 total scores, starting at week 2. The estimated probability of remission for duloxetine-treated patients (44%) was almost 3 times that of placebo patients (16%). Duloxetine significantly reduced painful physical symptoms in comparison with placebo. Discontinuation due to adverse events for duloxetine-treated patients (13.8%) compared favorably with the rates reported for SSRIs in other studies. Nausea, dry mouth, and somnolence were the most common adverse events; no significant incidence of hypertension was seen. CONCLUSION: Duloxetine, 60 mg/day, is a well-tolerated and effective treatment for MDD that reduces painful physical symptoms. These findings suggest that duloxetine may be a first-line treatment for patients with MDD and associated painful physical symptoms. |
| | |
Authors:
|
Michael J Detke; Yili Lu; David J Goldstein; John R Hayes; Mark A Demitrack |
Related Documents
:
|
18320404 - Psychopharmacological treatments of the long-term depression. 10084634 - Paroxetine in the treatment of primary insomnia: preliminary clinical and electroenceph... 1387484 - The effect of paroxetine on anxiety and agitation associated with depression. 16859434 - After the failure of citalopram for depression, what next? 20703414 - A preliminary open trial of olanzapine in paediatric acute and transient psychotic diso... 2945704 - A comparison of clindamycin phosphate 1 percent topical lotion and placebo in the treat... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: The Journal of clinical psychiatry Volume: 63 ISSN: 0160-6689 ISO Abbreviation: J Clin Psychiatry Publication Date: 2002 Apr |
Date Detail:
|
Created Date: 2002-05-09 Completed Date: 2002-05-31 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7801243 Medline TA: J Clin Psychiatry Country: United States |
Other Details:
|
Languages: eng Pagination: 308-15 Citation Subset: IM |
Affiliation:
|
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Ind 46285, USA. detke_michael@lilly.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antidepressive Agents / administration & dosage, therapeutic use* Depressive Disorder / diagnosis, drug therapy*, psychology Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Humans Male Pain Measurement Placebos Psychiatric Status Rating Scales Somatoform Disorders / diagnosis, drug therapy*, psychology Thiophenes / administration & dosage, therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antidepressive Agents; 0/Placebos; 0/Thiophenes; 116539-58-3/duloxetine |
| Comments/Corrections | |
Comment In:
|
J Clin Psychiatry. 2002 Apr;63(4):305-7
[PMID:
12000203
]
J Clin Psychiatry. 2003 Jan;64(1):96; author reply 96-7 [PMID: 12590632 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effect of reboxetine on depression in Parkinson's disease patients.
Next Document: Randomized trial of the efficacy of bright-light exposure and aerobic exercise on depressive symptom...